First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer (Q34104204)

24557339

31 July 2017

title

First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer (English)

1 reference

31 July 2017

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

Sharon H. Giordano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

Yu Shen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

1

Ya-Chen Tina Shih

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Ying Xu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

Wenli Dong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

21 February 2014

1 reference

24557339

Breast Cancer Research and Treatment

31 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

144

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

417-425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

Utilization of HER2 genetic testing in a multi-institutional observational study

7 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Patients' expectations about effects of chemotherapy for advanced cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Adjuvant trastuzumab in HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in Two Distinct Databases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Clinical Implications of the Cancer Genome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Discussions with physicians about hospice among patients with metastatic lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Development of a comorbidity index using physician claims data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10549-014-2874-1

Rare outcomes, common treatments: analytic strategies using propensity scores

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10549-014-2874-1

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

28 October 2018

https://api.crossref.org/works/10.1007/S10549-014-2874-1

Genomic testing and therapies for breast cancer in clinical practice

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148137

The performance of different propensity score methods for estimating marginal odds ratios

28 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10549-014-2874-1

Does reimbursement influence chemotherapy treatment for cancer patients?

21 January 2018

1 reference

12 December 2020

Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients

1 reference

12 December 2020

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

1 reference

12 December 2020

Heart of darkness: the downside of trastuzumab

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Trastuzumab induced cardiomyopathy: wider implications for cardio-oncology

1 reference

12 December 2020

A weighting analogue to pair matching in propensity score analysis

1 reference

12 December 2020

10.1007/S10549-014-2874-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24557339 AND SRC:MED&resulttype=core&format=json

7 June 2020

24557339

1 reference